What does this research mean for the field?

Moxonidine is an effective antihypertensive agent that provides comparable blood pressure control to other drug classes but with a more favorable side-effect profile due to its selective I1-imidazoline receptor agonism. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the hemodynamic actions, therapeutic efficacy, tolerability, and metabolic effects of the selective I1-imidazoline receptor agonist moxonidine in hypertension.

January 1, 2000Journal of Cardiovascular Pharmacology

Moxonidine: A New and Versatile Antihypertensive

View Full Paper

Ask AI

Bookmark

Why the study?

Does moxonidine improve blood pressure control and tolerability in patients with hypertension compared to other antihypertensive drugs?

Population

Patients with hypertension

Comparison

Moxonidine 0.2 to 0.4 mg per day vs Other antihypertensive drug classes

Design

Review

Authors

FMFranz H. MesserliSt. Luke's-Roosevelt Hospital Center

Discussion

Member takes

Implication

May support moxonidine as alternative for hypertension with better tolerability; leaves open confirmation in prospective RCTs.

Key Points

To review the hemodynamic actions, therapeutic efficacy, tolerability, and metabolic effects of the selective I1-imidazoline receptor agonist moxonidine in hypertension.
Reviewed acute and long-term hemodynamic studies measuring systemic vascular resistance, heart rate, cardiac output, stroke volume, and sympathetic biomarkers.
Evaluated clinical trials assessing antihypertensive efficacy and 24-hour ambulatory blood pressure monitoring across daily doses of 0.2 to 0.4 mg compared with standard drug classes.
Moxonidine decreased arterial pressure by reducing systemic vascular resistance and lowering sympathetic markers (norepinephrine, epinephrine, and plasma renin activity) without altering heart rate or cardiac output.
Daily administration of 0.2 to 0.4 mg provided blood pressure control comparable to standard antihypertensive classes, including enalapril, alongside regression of left ventricular hypertrophy and improved side-effect tolerability due to minimal alpha2-receptor binding.

Structured PICO

Does moxonidine improve blood pressure control and tolerability in patients with hypertension compared to other antihypertensive drugs?

Population

Patients with hypertension

Intervention

Moxonidine 0.2 to 0.4 mg per day

Comparator

Other antihypertensive drug classes (clonidine, diuretics, alpha-blockers, beta-blockers, calcium antagonists, and ACE inhibitors)

Outcome

Blood pressure controlsurrogate

Moxonidine is an effective and well-tolerated centrally acting antihypertensive agent that lowers blood pressure similarly to other drug classes.

Limitations

Potential advantages need to be properly evaluated in a prospective morbidity and mortality study

Cite This Study

Franz H. Messerli (2000) studied this question.

synapsesocial.com/papers/6a14ae16fc9ca4e5c9a60182 https://doi.org/10.1097/00005344-200000004-00007

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Moxonidine: A New and Versatile Antihypertensive

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Moxonidine: A New and Versatile Antihypertensive

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider